W
Won Ki Kang
Researcher at Samsung Medical Center
Publications - 385
Citations - 18420
Won Ki Kang is an academic researcher from Samsung Medical Center. The author has contributed to research in topics: Cancer & Capecitabine. The author has an hindex of 59, co-authored 368 publications receiving 14746 citations. Previous affiliations of Won Ki Kang include Sungkyunkwan University & Samsung.
Papers
More filters
Journal ArticleDOI
Treatment of hemodialyzed patients with sunitinib in renal cell carcinoma.
Silvia Park,Jeeyun Lee,Se Hoon Park,Joon Oh Park,Won Ki Kang,Young Suk Park,Jin Hyun Cho,Ho Yeong Lim +7 more
TL;DR: The toxicity of and response to sunitinib in dialyzed patients seem to be comparable to those in patients with normal renal function, however, due to the limitations of this study, prospective clinical trials with pharmacokinetic studies in a larger cohort of patients are required.
Journal ArticleDOI
NTRK gene amplification in patients with metastatic cancer
Journal ArticleDOI
A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology.
Jun Ho Yi,Jung Hun Kang,In Gyu Hwang,Hee Kyung Ahn,Hyun Jin Baek,Soon Il Lee,Do Hyoung Lim,Young Woong Won,Jun Ho Ji,Hyo Song Kim,Sun Young Rha,Sung Yong Oh,Kyung Eun Lee,Taekyu Lim,Chi Hoon Maeng,Moon Jin Kim,Seung Tae Kim,Jeeyun Lee,Joon Oh Park,Young Suk Park,Ho Yeong Lim,Won Ki Kang,Se Hoon Park +22 more
TL;DR: The data may suggest that even in Asian patients and patients with PDH, trastuzumab-based chemotherapy could be associated with improved clinical outcomes in patients with HER2-positive gastric cancer.
Journal ArticleDOI
A phase II open-label trial of dacomitinib monotherapy in patients with HER2-positive advanced gastric cancer after failure of at least one prior chemotherapy regimen.
TL;DR: Considering the heavily pretreated nature of enrolled patients, the dacomitinib is active and safe treatment option in HER2 (+) AGC patients.
Journal ArticleDOI
Salvage chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for previously treated metastatic or recurrent esophageal squamous cell carcinoma
Byeong-Bae Park,Young-Hyuck Im,In Gyu Hwang,Sang Cheol Lee,Jin Seok Ahn,Myung-Ju Ahn,Ho-Yeong Lim,Won Ki Kang,Keunchil Park +8 more
TL;DR: MIC chemotherapy has modest activity as a salvage regimen with tolerable toxicity, and could be one of the chemotherapy treatment options for patients with advanced or recurrent esophageal squamous cell carcinoma for whom previous chemotherapy has failed.